IP Library Granted Patent US 8,815,542
Granted Patent B2
US 8,815,542 · App. 13/787,400 · Granted Aug 26, 2014

Unnatural reactive amino acid genetic code additions

Inventors: Alexander Deiters (La Jolla, CA); T. Ashton Cropp (Richmond, VA); Jason W. Chin (Cambridge, GB); J. Christopher Anderson (San Francisco, CA); Peter G. Schultz (La Jolla, CA)
Assignee: The Scripps Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,542
App. No.
13/787,400
Granted
Aug 26, 2014
Kind
B2
Abstract

This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.

Claims (12)

1. A composition comprising a protein, an antibody or antibody fragment, wherein the protein, antibody or antibody fragment comprises at least one unnatural amino acid comprising a reactive group for the attachment of a molecule by a cycloaddition reaction, wherein the at least one unnatural amino acid is incorporated site-specifically into the protein, antibody or antibody fragment in vivo in a eukaryotic cell using an orthogonal translation system; and

wherein the at least one unnatural amino acid is incorporated site-specifically at any site other than a lysine or cysteine site in the protein, antibody or antibody fragment.

2. The composition of claim 1 , wherein the cycloaddition reaction is a [3+2] cycloaddition reaction.

3. The composition of claim 1 , wherein the molecule is selected from the group consisting of a small organic molecule, a cytotoxic compound, a second protein or polypeptide, and a prodrug.

4. The composition of claim 1 , wherein the molecule comprises a radionuclide.

5. The composition of claim 1 , wherein the at least one unnatural amino acid is a cyclic unnatural amino acid.

6. The composition of claim 1 , wherein the at least one unnatural amino acid is p-azido-L-phenylalanine, p-benzoyl-phenylalanine or p-propargyloxyphenylalanine.

7. The composition of claim 1 , wherein the at least one unnatural amino acid is a photoreactive unnatural amino acid.

8. The composition of claim 7 , wherein the photoreactive unnatural amino acid comprises a p-azido-L-phenylalanine, a p-benzoyl-phenylalanine or a p-propargyloxyphenylalanine.

9. The composition of claim 1 , wherein the at least one unnatural amino acid comprises a p-propargyloxyphenylalanine.

10. The composition of claim 1 , wherein the antibody or antibody fragment is selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies, Fab fragments, fragments produced by an Fab expression library, and single chain antibody fragments.

11. The composition of claim 1 , wherein the protein, antibody or antibody fragment specifically binds a tumor-specific antigen, or wherein the antibody or antibody fragment mediates antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-mediated lysis (CML).

Continuity (6)
Continuation 13135129 · Jun 23, 2011
Continuation 10561121
Provisional Application 60493014 · Aug 5, 2003
Provisional Application 60496548 · Aug 19, 2003
Provisional Application 60479931 · Jun 18, 2003
Related Publication 20130245230A1 · Sep 19, 2013